Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04642404 · ClinicalTrials.gov registry record · Phase 1

CBD for Dental Pain

A Phase 1 study of Toothache and Odontalgia, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target
1
Study location

NCT04642404 is a Phase 1 study of Toothache and Odontalgia that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants, below the 143-participant average among 3 other Toothache trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04642404, a Phase 1 study of Toothache and Odontalgia, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Epidiolex 100 mg/mL Oral Solution

Study Locations (1)

Texas

  • The University of Texas Health Science Center at San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2021-03-01
Est. Completion 2023-03-13
Phase Phase 1

What the Registry Record Tells You About NCT04642404

The ClinicalTrials.gov registry entry for NCT04642404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 3 other Toothache trials with a reported enrollment target (55% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Toothache appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04642404 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04642404 about?

NCT04642404 is a clinical study titled "CBD for Dental Pain". The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.

What is the current status of trial NCT04642404?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2021-03-01. Estimated completion is 2023-03-13.

What conditions does trial NCT04642404 study?

This clinical trial studies the following conditions: Toothache, Odontalgia.

What interventions are being tested in trial NCT04642404?

The interventions under investigation include: Placebo (DRUG), Epidiolex 100 mg/mL Oral Solution (DRUG).

Who is sponsoring clinical trial NCT04642404?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04642404 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Toothache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.